Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3Dionysos Slaga, Teemu T. Junttila, Ji Li et al.|Science Translational Medicine|2018Cited by 141
Design and Pharmacokinetic Characterization of Novel Antibody Formats for Ocular TherapeuticsKapil Gadkar, Justin M. Scheer, Cinthia V. Pastuskovas et al.|Investigative Ophthalmology & Visual Science|2015Cited by 68